Literature DB >> 17082447

A century of Alzheimer's disease.

Michel Goedert1, Maria Grazia Spillantini.   

Abstract

One hundred years ago a small group of psychiatrists described the abnormal protein deposits in the brain that define the most common neurodegenerative diseases. Over the past 25 years, it has become clear that the proteins forming the deposits are central to the disease process. Amyloid-beta and tau make up the plaques and tangles of Alzheimer's disease, where these normally soluble proteins assemble into amyloid-like filaments. Tau inclusions are also found in a number of related disorders. Genetic studies have shown that dysfunction of amyloid-beta or tau is sufficient to cause dementia. The ongoing molecular dissection of the neurodegenerative pathways is expected to lead to a true understanding of disease pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17082447     DOI: 10.1126/science.1132814

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  539 in total

Review 1.  An inherited variable poly-T repeat genotype in TOMM40 in Alzheimer disease.

Authors:  Allen D Roses
Journal:  Arch Neurol       Date:  2010-05

2.  Three- and four-repeat Tau coassemble into heterogeneous filaments: an implication for Alzheimer disease.

Authors:  Ayisha Siddiqua; Martin Margittai
Journal:  J Biol Chem       Date:  2010-10-04       Impact factor: 5.157

Review 3.  Are tangles as toxic as they look?

Authors:  Tara L Spires-Jones; Katherine J Kopeikina; Robert M Koffie; Alix de Calignon; Bradley T Hyman
Journal:  J Mol Neurosci       Date:  2011-06-03       Impact factor: 3.444

4.  The protein phosphatase PP2A/Bα binds to the microtubule-associated proteins Tau and MAP2 at a motif also recognized by the kinase Fyn: implications for tauopathies.

Authors:  Jean-Marie Sontag; Viyada Nunbhakdi-Craig; Charles L White; Shelley Halpain; Estelle Sontag
Journal:  J Biol Chem       Date:  2012-03-08       Impact factor: 5.157

5.  Amyloid precursor protein and tau transgenic models of Alzheimer's disease: insights from the past and directions for the future.

Authors:  Naruhiko Sahara; Jada Lewis
Journal:  Future Neurol       Date:  2010-05-01

6.  Neuronal DNA content variation (DCV) with regional and individual differences in the human brain.

Authors:  Jurjen W Westra; Richard R Rivera; Diane M Bushman; Yun C Yung; Suzanne E Peterson; Serena Barral; Jerold Chun
Journal:  J Comp Neurol       Date:  2010-10-01       Impact factor: 3.215

7.  Permeability transition pore-mediated mitochondrial superoxide flashes mediate an early inhibitory effect of amyloid beta1-42 on neural progenitor cell proliferation.

Authors:  Yan Hou; Paritosh Ghosh; Ruiqian Wan; Xin Ouyang; Heping Cheng; Mark P Mattson; Aiwu Cheng
Journal:  Neurobiol Aging       Date:  2013-11-13       Impact factor: 4.673

8.  L-arginine and Alzheimer's disease.

Authors:  Jing Yi; Laura L Horky; Avi L Friedlich; Ying Shi; Jack T Rogers; Xudong Huang
Journal:  Int J Clin Exp Pathol       Date:  2008-10-02

Review 9.  Amyloid beta-protein assembly as a therapeutic target of Alzheimer's disease.

Authors:  Ghiam Yamin; Kenjiro Ono; Mohammed Inayathullah; David B Teplow
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

Review 10.  Zinc and its effects on oxidative stress in Alzheimer's disease.

Authors:  Ye Yuan; Fenglan Niu; Ya Liu; Na Lu
Journal:  Neurol Sci       Date:  2014-02-13       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.